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The potassium channel opener levcromakalim
causes expansive remodelling of experimental
vein grafts
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Alun H. Davies, FRCS, MD,a and Janet T. Powell, MD, PhD,a London, United Kingdom
Background: Maintenance of luminal area is essential for the optimal performance of venous bypass grafts. However,
injury and response to the arterial circulation evoke vascular remodelling that favors intimal hyperplasia, with luminal
encroachment and inward remodelling. Potassium channel-opening drugs reduce tissue workload and peripheral vascular
resistance and through these mechanisms could favor outward or expansive remodelling of vein grafts. We tested the
hypothesis that levcromakalim, a potassium channel opener, would enhance expansive remodelling in vein grafts.
Methods: A randomized, double-blind, placebo-controlled trial was conducted in 33 rats with vena cava-to-aorta bypass
grafts. Drugs were administered via osmotic pump for 7 days after surgery. Half the cohort had bromodeoxyuridine
(BrdU) infused at day 6. Morphometric analysis was conducted of pressure perfusion-fixed grafts harvested at 1 week and
4 weeks.
Results:At 1week, lumen area was similar in both groups (1.82 0.39mm2 placebo vs 1.85 0.36mm2 levcromakalim),
although medial cell density and BrdU staining were significantly increased in the placebo group. At 4 weeks, lumen area
was unchanged in the placebo group (1.88  0.51 mm2) but had increased to 2.32  0.46 mm2 in the levcromakalim
group (P  .039 vs 1 week), with a very significant reduction in the intimal area (levcromakalim, 0.06  0.02 mm2 vs
placebo, 0.33  0.17 mm2; P  .001).
Conclusions: Early, short-term treatment with levcromakalim favors expansive remodelling of experimental vein grafts to
mimic the effect of external stenting. This expansive remodelling was associated with a reduction in medial cell
proliferation at 1 week.
Clinical Relevance: Critical limb ischemia can be treated by bypass surgery or angioplasty, but inward remodelling with
restenosis is a common problem. There has been little previous experimental work to identify treatments associated with
expansive remodelling, which would increase the chances of vessel patency. Here, in a randomized trial, we show that
short-term treatment with a potassium channel opener (a class of drug that can be used to treat hypertension) results in
strong, expansive remodelling, with increases the lumen area and graft size of experimental vein grafts by>25%. (J Vasc
Surg 2006;44:159-65.)The concept of using saphenous vein for bypassing
diseased coronary or peripheral arteries was amajor advance
for cardiovascular surgery. That vein, with anatomic and
physiologic functions suited to a low-pressure minimally
pulsatile circulation, can be excised and used as an arterial
conduit is remarkable, this being achieved through a pro-
cess of vascular remodelling.1 Saphenous vein has myo-
genic tone and constricts in response to acute increases in
intraluminal pressure.2 To prevent this occurring in clinical
practice, vein is stretched beyond its elastic limit or is
treated with papaverine before implantation. Overdisten-
sionmay leave a vessel of larger diameter than the arteries to
which it is anastomosed.
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doi:10.1016/j.jvs.2006.02.063Unsurprisingly, intimal hyperplasia results in the in-
ward remodelling of saphenous vein grafts. Excessive inti-
mal hyperplasia narrows the lumen of venous bypass grafts
so that symptoms recur and graft failure is a likely sequela.
Graft failure occurs in up to 30% of venous bypass grafts,
intimal hyperplasia being a common cause of the graft
failures occurring between 1 and 24 months after sur-
gery.3,4
A large body of work of experimental work has been
directed at attenuating the development of intimal hyper-
plasia in vein grafts, with intimal thickness being the prin-
cipal outcome measure of most studies.5-7 Surprisingly
lumen area, a critical determinant of graft function, has
received far less attention. External stenting of vein grafts is
one of the few treatments that has been reported to lead to
expansive remodelling, or an increase in the lumen area.8,9
External stenting would appear to be an important
advance to improve the outcome of venous bypass grafts in
patients. Unfortunately, technical difficulties in the dis-
eased human vasculature, together with an increasing risk
of infection of tissue already ischemic, might underlie the
absence of successful clinical trials of external vein graft
stenting.We therefore searched for a possible pharmaceutic
agent that might, like external stenting, cause expansive
159
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and metabolic changes in vein grafts trigger the long-term
vascular remodelling responses,10-13 such an agent need
only be administered for a short time.
Adenosine triphosphate (ATP)-dependent potassium
(KATP) channels link cellular metabolism to membrane
function and cellular excitability. Potassium channel-
opening drugs such as pinacidil and diazoxide are used
clinically, usually for treatment of hypertension. They re-
duce workload in angina, hypertension, and peripheral
vascular disease, and they are vasodilators and reduce pe-
ripheral resistance.
KATP channels are present in human saphenous vein,
and levcromakalim (a benzopyran derivative) is the most
potent of the potassium channel openers for this tissue.14
The metabolic effects to reduce oxidative stress and pre-
serve mitochondrial function of these benzopyran deriva-
tives suggest that they may be useful in ischemic precondi-
tioning. KATP channels are also present in endothelium,
where they are upregulated by shear stress, and in vascular
smooth muscle.15,16
For all of these reasons, we considered that potassium
channel openers could provide a metabolic mimic of exter-
nal stenting. Here, we test the hypothesis that levcro-
makalim causes expansive remodelling of experimental vein
grafts.
METHODS
Animals and drug delivery. Studies were performed
using syngenic male Lewis rats weighing 200 to 250 grams.
All animals received humane care in accordance with the
Home Office Animals (Scientific Procedures) Act 1986
(HMSO 1990). Experiments were conducted under
Project Licence PPL 70/4370, Personal Licence PIL 70/
15215. Animals were randomized by an independent sci-
entist to receive levcromakalim or a placebo. Osmotic
pumps (ALZET model 2ML1, Alza Corporation, Moun-
tain View, Calif) containing either levcromakalim (1.62
mg/mL, 20% v/v ethanol) or an identical-looking placebo
(20% v/v ethanol) were implanted subcutaneously 24
hours before aortocaval grafting. A tunnelled catheter en-
abled intravenous drug or placebo delivery via the external
jugular vein (n  33).
Levcromakalim assay. Plasma levcromakalim was as-
sayed using high performance liquid chromatography
(HPLC)-multiple reaction monitoring in the presence of
another benzopyran, HOE234, a gift from Hoechst Phar-
maceuticals (Frankfurt, Germany) as an internal standard.
Briefly, plasma (75 L) was treated with ice-cold acetoni-
trile (0.4 mL) to precipitate proteins, extracted with Oasis
cartridges (Waters, St Quentin-en-Yvelines, France) and
purified by HPLC on a Hichrom rpb column (10 cm  2
mm) eluting at 0.1 mL/min with a linear gradient of
acetonitrile:water:formic acid (30:70:0.1-60:40:0.1).
Levcromakalim eluted at 11.5 minutes and HOE234 at
16.2 minutes. The eluate was passed into the ve ion
electrospray source of a Micromass Quattro II triple quad-
rupole mass spectrometer (Waters, St Quentin-en-Yvelines,France) for analysis in the multiple reaction-monitoring
mode using ion transitions m/z 287¡160 (levcro-
makalim) and m/z 402-275 (HOE234). Levcromakalim
was quantified against a 6-point extracted standard curve.
The limit of detection was set at 2.5 ng/75L and the limit
of quantification at 5 ng/75 L with a corresponding
coefficient of variation of 10.4%.
Operative procedures. Aortocaval bypass grafts were
performed by harvesting the supradiaphragmatic portion of
the inferior vena cava (IVC) from a donor rat and inserting
a 1- to 1.2-cm segment length (diameter up to 20% greater
than the recipient aorta) into the infra-abdominal aorta of
the recipient rat under 10 magnification using end-to-
end anastomoses with interrupted 10-0 nylon sutures.17
Osmotic pumps were removed at 7 days. Plasma samples
were taken on day 1 and day 7 for levcromakalim assay.
Rats, for sacrifice at 7 days, received intraperitoneal injec-
tions of bromodeoxyuridine (BrdU) 100 mg/kg at 17
hours, 9 hours, and 1 hour before graft harvesting. Grafts
were harvested at 1 and 4 weeks by using perfusion fixation
with 10% formaldehyde at 90 mm Hg.
Sectioning and staining. Grafts were divided into
proximal, mid, and distal segments after excision of anasto-
moses and were embedded in paraffin. Consecutive mid-
graft 3m sections (n 36) were stained with hematoxylin
and eosin (H&E) and elastic van Gieson (EVG) at six-
section intervals. Immunostaining for BrdUwas performed
on similar mid-graft sections (n6 for each graft) from
1-week grafts.18
Image analysis. Microscopic images of the vein grafts
were analyzed by a computer-assisted image analysis system
(AnalySIS 3.1, Soft Imaging System, Analysis Imaging,
Munster, Germany). All measurements were made with the
observer blind to the treatment group. Captured images of
EVG sections at 4 magnification were used for morpho-
metric analysis (n 6 per graft). The EVG stained sections
were used to define the area enclosed by the endothelium as
the lumen, the area between the endothelium and the
internal elastic lamina defined the intima, the area between
the internal and external elastic lamina (EEL) defined the
media, and the overall vein graft size was measured as the
area contained within the EEL (Fig 1). The elastic lamina
boundaries were selected by locating the innermost fenes-
trated elastic lamina adjacent to the endothelium or intima
(IEL) and the outermost lamella defining the border be-
tween muscular media and the looser connective tissue of
the adventitia (EEL).
In the 4-week group, morphometric parameters were
assessed in proximal, mid, and distal graft segments, and
intimal/medial area ratios were calculated. In the 1-week
group, mid-graft sections were analyzed for luminal area
and combined intimal and medial area, as a discrete intimal
layer could not be identified.
Captured images of H&E stained sections at 40
magnification were used for quantification of cell density.
Six fields in six consecutive sections were analyzed per
mid-graft cross section at 45° intervals (n  36 per graft
segment). Intimal and medial boundaries were confirmed
atom
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After defining intimal andmedial regions, nuclear counting
was performed, and cell density measurements were calcu-
lated. BrdU staining was quantified as a marker of medial
cell proliferation in 1-week grafts and quantified on a scale
of 0 (none) to 3 (most) in the medial layer of the mid-graft
wall.18
Statistics. Power calculations were based on a 25%
increase in luminal area, giving a sample size of eight a
power of 80% at the 5% significance level. Means and
standard deviations were calculated for measured parame-
ters. Comparisons between groups for morphometric and
cell density analyses were made using the two-sample Wil-
coxon rank-sum (Mann-Whitney) test. BrdU staining
scores between groups were compared using Fischer’s exact
test.
RESULTS
Thirty-three animals successfully recovered from anes-
thesia after aortocaval bypass. Operative mortality and
long-term survival were very similar in the two groups.
Preoperatively, the placebo and levcromakalim groups
weighed 232  6.3 grams and 230  10.3 grams, respec-
tively, and there was no difference between the groups in
weight gain at either 1 week or 4 weeks after surgery. One
animal from the levcromakalim group developed sepsis
secondary to pump infection at day 21, and another animal
from the placebo group had an occluded graft at 4 weeks;
both were excluded from the morphometric analysis.
The infusion dose of levcromakalim (860 ng/min/kg
to achieve a steady state plasma concentration of 32.7
ng/mL) was selected as a result of pharmacokinetic and
pharmacodynamic studies that showed levcromakalim has a
half-life of 32.5 minutes and a limited hypotensive effect in
the rat at a plasma concentration of 33 ng/mL (Fig 2). In
animals receiving levcromakalim, the target plasma concen-
tration of plasma levcromakalim was 33ng/mL, a concen-
tration at which KATP channels appeared to be activated
(relaxation of vein rings precontracted with phenylephrine)
but with only a minimal reduction (5%) in mean arterial
Fig 1. Schematic representation of anblood pressure.EVG staining of vein ring sections showed the presence
of elastic laminae (Fig 3). The mean levcromakalim concen-
tration at day 1 was 36.8 10.7 ng/mL, and it was 33.7
11.7 ng/mL at day 7. No levcromakalim was detected in
plasma samples taken from the control group at either day
1 or day 7. An initial assessment of intimal and medial areas
at proximal, mid-graft, and distal graft segments in 4-week
vein grafts found no significant differences in these areas for
the different graft segments; therefore, the mid-graft sec-
tion was chosen for all further detailed analyses.
The medial thickness of normal IVC at grafting was 40
m, but by 1 week, the medial thickness was much greater
than 40 m in both levcromakalim and placebo groups (Fig
ic landmarks and measurements made.
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Fig 2. Pharmokinetic studies of levcromakalim. A Hypotensive
effect of levcromakalim in anesthetized normotensive rats. Blood
pressure (mean SD) was transduced from an intra-aortic line, in
3 rats, in response to intravenous levcromakalim. B Rat plasma
levcromakalim concentration following a single bolus of levcro-
makalim (100 g/kg). The decay curve was identical in 2 rats,
giving a half-life of 32.5 minutes.4). Although the IEL could be defined easily at this time
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fore, combined intimal plus medial areas were calculated by
subtracting the luminal area from the area contained within
the EEL. Although the adventitia was intact at vein graft
harvest, the adventitial layer was stripped off during pro-
cessing in some histologic sections (Fig 4, D). Therefore,
morphometric analysis of the adventitia was not included.
All the morphometric results at 1 week are given in Table I.
The reduction in medial cell density in the levcro-
makalim group was confirmed by BrdU staining, which was
Fig 3. Rat thoracic vena cava. Elastic van Gieson staining shows
the elastic laminae. The scale bar represents 50 .
Fig 4. Vein grafts at 1 week. Examples from the placebo group
are shown in A stained with hematoxylin and eosin (H&E) and in
C stained with elastic van Gieson (EVG). Examples from the
levcromakalim group are shown in B (H&E) and D (EVG). Note
the periadventitial stripping (the result of processing for histology)
in D. The scale bar represents 100 .observed in the media and adventitia of 1-week grafts.Medial BrdU staining is presented as a score because of
weak H&E counterstaining in some sections. The median
proliferation scores for the medial layer were 1 in the
levcromakalim group and 3 in the placebo groups (P 
.02), and representative staining is shown in Fig 5.
By 4 weeks, a separate intimal area was clearly discernible
in all vein grafts, although the intimal thickening appeared
much greater in the placebo group than in the levcromakalim
group (Fig 6). The increased lumen area of the levcromakalim
group is evident in Fig 6, which summarizes the morphomet-
ric findings.Detailedmorphometric results at 4weeks, includ-
ing intimal area, are given in Table II.
Remodelling characteristics were assessed by compar-
ing changes in lumen area and total vein graft size between
1 and 4 weeks (Fig 7). Vein graft size and lumen area
significantly increased in the levcromakalim treated group
during this time. Consistent with an expansive remodelling
process, the mean increase in vein graft size was 0.65 mm2
(28%) (P .002), and the mean increase in lumen area was
0.46 mm2 (26%) (P  .039). No significant change was
noted in lumen area or vein graft size in the placebo group
between 1 and 4 weeks.
DISCUSSION
The hypothesis that the KATP channel opener levcro-
makalim favors the expansive remodelling of vein grafts is
supported by the results of this study, which show that a
modest dose of levcromakalim was associated with a 25%
increase in both vein graft and lumen size at 4 weeks, these
changes being accompanied by a 5-fold reduction of inti-
mal area. Although expansive remodelling is a desirable
clinical outcome, most previous experimental studies have
focused on the development of intimal hyperplasia rather
than vein graft dimensions.4
It is encouraging that lumen and vein graft area are
becoming recognized as important outcome measures. For
instance, one of the early events underlying the develop-
ment of intimal hyperplasia is likely to be the formation of
microthrombi on the damaged endothelial surface.19 A
recent study has indicated that thrombin inhibitors cause
expansive remodelling of expansive vein grafts.20 Other
early events in vein graft remodelling include altered cell-
signalling processes leading to the degradation of muscle
actin filaments in response to mechanical stretch and en-
hanced smooth muscle cell proliferation.21
The synergistic effects of levcromakalim to cause vaso-
dilation and excitation-metabolic coupling are likely to
minimize workload on the new vein graft and hence control
cell-signalling events to limit degradation of actin filaments.
This in turn appears to have led to a reduced medial cell
proliferation and BrdU staining. Levcromakalim also de-
creases peripheral vascular resistance to encourage high
flow through the graft, which may contribute to favorable
expansive remodelling.22
Intimal hyperplasia formation is associated with in-
ward, constrictive remodelling processes, with progressive
luminal compromise leading to the development of hemo-
dynamically significant vein graft stenoses strongly impli-
m.
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metric remodeling processes in experimental vein grafts
have rarely been measured, the features that characterize
expansive arterial remodelling have been recently de-
scribed.
There is clinical evidence that expansive remodelling of
vein grafts occurs even in diseased vein grafts.23 The bal-
Table I. Morphometric measurements and cell count in v
Placebo
Combined intimal and medial area (mm2) 1.07
Lumen area (mm2) 1.82
Vein graft size (mm2) 2.81
Medial cell density (cells/mm2) 5530
BrdU score (median) 
BrdU, Bromodeoxyuridine.
*Mann-Whitney.
†Fischer’s exact.
Fig 5. Bromodeoxyuridine (BrdU) staining of vein
levcromakalim treated group showing 1 medial staini
medial staining for BrdU. The scale bar represents 100 
Fig 6. Vein grafts at 4 weeks. Examples from the placebo group
are shown in A stained with hematoxylin and eosin (H&E) and in
C stained with elastic van Gieson (EVG). Examples from the
levcromakalim group are shown in B (H&E) and D (EVG). The
scale bar represents 100 m.ance of proteolytic and inflammatory activities is one im-portant item of discussion,24-26 although blood flow also is
likely to have an important influence on remodelling. Re-
duced late constrictive remodelling has been reported in
experimental arterial angioplasty after early metalloprotein-
ase inhibition.27
Although the conclusions of our study are supported by
strong methodology, particularly the double-blinding as-
pects, whereby an independent person randomized the
animals to treatment with placebo or levcromakalim and
the observers remained ignorant of treatment allocation
until the statistical analysis of morphometric results had
been completed, the study was conducted in healthy, non-
atherosclerotic vessels. Our choice of the 4-week time point
as one where the remodelling process has stabilized is
supported by the evidence of others.28 However, most
previous murine studies have used vena cava-to-carotid
bypass grafts. Our choice of vena cava-to-aortic grafts per-
mitted greater flexibility of anastomotic techniques, per-
mitting end-to-end anastomoses in a high flow situation,
and perhaps this contributed to similar levels of intimal
hyperplasia identified along the graft in contrast to the vena
cava to carotid model where intimal hyperplasia is greatest
at the anastomoses.29 Because the vein grafts were in a high
flow situation, we did not measure graft blood flow or
peripheral vascular resistance. We therefore cannot com-
ment on how the possible effect of levcromakalim to reduce
peripheral vascular resistance might have influenced our
results; this property of levcromakalim is likely to assume
greater importance for the properties of femoral artery vein
rafts at 1 week
8) Levcromakalim (n  8) P
8 0.38  0.05 .001*
9 1.85  0.36 .898*
9 2.23  0.36 .029*
0 3420  280 .001*
1 .02†
at 1 week. A, Control 0 staining. B, Example of
r BrdU. C, Example from placebo group showing 3ein g
(n 
 0.2
 0.3
 0.5
 76
3grafts
ng fografts. Neither are we able to comment on any morpho-
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tory processing caused adventitial detachment in a few
samples. Because our study was directed at identifying a
pharmacologic alternative to external stenting, it is relevant
that external stenting also causes expansive remodelling in
an atherosclerotic model using apoE(-/-) mice.30
The possibility remains that the early expansive remod-
elling of vein grafts would be associated with aneurysmal
dilatation with longer follow-up, later atherosclerotic
changes in the vein graft, or further important hemody-
namic changes. The long-term follow up that would be
necessary to investigate these matters in experimental vein
grafts is not condoned by our regulatory authorities. For
now, we only can rely on the good evidence to indicate that
the remodelling of experimental vein grafts is complete by 4
weeks.15
There are several possibilities for further studies to
explore in more detail the molecular mechanisms whereby
levcromakalim causes expansive remodelling of vein grafts.
These include more detailed immunochemical analysis of
the 1-week vein graft sections for relevant markers, such as
caspase3,21 and quantification of macrophages and other
types of inflammatory cells. If translation to patients is
considered, the next steps should include a trial of levcro-
makalim in an atherosclerotic model using end-to-side
anastomoses.30
CONCLUSION
We have identified a simple treatment associated with
the expansive remodeling of experimental vein grafts. This
goal of expansive remodelling is likely to have greater
clinical relevance than the goal of reduction of intimal
hyperplasia.
We thank Louise C Brown for the independent statis-
tical analyses.
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